ut-logo website  
 
Log in
Express registration and login!
If you have a Facebook or LinkedIN account, use one of the buttons on the left to either login or create a new account.

Log in

 

You are here: Home GU Cancers mCRPC Conferences DGU 2011 Session Highlights Bladder Cancer Highlights
DGU 2011 - Prospective, randomized, double-blind, multicenter phase-II trial comparing gemcitabine/cisplatinum +/- sorafenib in locally advanced or metastatic urothelial cancer of the bladder (AUO-trial AB 31/05) - Session Highlights

DGU 2011 - Prospective, randomized, double-blind, multicenter phase-II trial comparing gemcitabine/cisplatinum +/- sorafenib in locally advanced or metastatic urothelial cancer of the bladder (AUO-trial AB 31/05) - Session Highlights

Published on 27 September 2011
  • Print
HAMBURG, GERMANY (UroToday.com) - In this trial, the addition of sorafenib (versus placebo) to first-line therapy with gemcitabine/cisplatinum (gem/cis) in patients with locally advanced or metastatic urothelial cancer of the bladder was tested.To read more, a FREE Urotoday registration is required. Click here to register or login above.
To read UIJ content, a separate subscription is required.
Tags:

Conferences Menu

Disease Topics